Applying multiomics to novel target discovery in immuno-oncology
Immuno-Oncology Insights 2023; 4(6), 249–255
Published: 8 August
Eran Ophir, Yaron Turpaz
Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with (pictured from left to right)Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about the advantages of using multi-omic and computational approaches for the discovery of novel targets and mechanisms of action of novel drug candidates in immuno-oncology.